References
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57–70. https://doi.org/10.1016/S0092-8674(00)81683-9
- Huelsken J, Hanahan D. A subset of cancer-associated fibroblasts determines therapy resistance. Cell. 2018 Feb 8;172(4):643–644. https://doi.org/10.1016/j.cell.2018.01.028
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013
- Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020 Mar;20(3):174–186. DOI:https://doi.org/10.1038/s41568-019-0238-1.
- Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2018 Nov 23.
- Maman S, Witz IP. A history of exploring cancer in context. Nat Rev Cancer. 2018 Jun;18(6):359–376.
- Dvorak HF, Underhill LH, Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986 Dec 25;315(26):1650–1659. https://doi.org/10.1056/NEJM198612253152606
- Sappino AP, Skalli O, Jackson B, et al. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int J Cancer. 1988 May 15;41(5):707–712. https://doi.org/10.1002/ijc.2910410512
- Ronnov-Jessen L, Petersen OW, Koteliansky VE, et al. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest. 1995 Feb;95(2):859–873. DOI:https://doi.org/10.1172/JCI117736.
- Olumi AF, Grossfeld GD, Hayward SW, et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999 Oct 1;59(19):5002–5011. https://doi.org/10.1186/bcr138
- Bourhis X D-L, Berthois Y, Millot G, et al. Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. Int J Cancer. 1997 Mar 28;71(1):42–48. https://doi.org/10.1002/(SICI)1097-0215(19970328)71:1<42::AID-IJC9>3.0.CO;2-3
- Orimo A, Weinberg RA. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol Ther. 2007 Apr;6(4):618–619.
- Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol. 2004;48(5–6):509–517.
- Sugimoto H, Mundel TM, Kieran MW, et al. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther. 2006 Dec;5(12):1640–1646. DOI:https://doi.org/10.4161/cbt.5.12.3354.
- Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer. 2004 Aug;45(Suppl 2):S163–75.
- De Wever O, Nguyen QD, Van Hoorde L, et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 2004 Jun;18(9):1016–1018. DOI:https://doi.org/10.1096/fj.03-1110fje.
- Pietras K, Sjoblom T, Rubin K, et al. PDGF receptors as cancer drug targets. Cancer Cell. 2003 May;3(5):439–443. DOI:https://doi.org/10.1016/S1535-6108(03)00089-8.
- Erez N, Truitt M, Olson P, et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappab-dependent manner. Cancer Cell. 2010 Feb 17;17(2):135–147. https://doi.org/10.1016/j.ccr.2009.12.041
- Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010 Nov 5;330(6005):827–830. https://doi.org/10.1126/science.1195300
- True LD, Zhang H, Ye M, et al. CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol. 2010 Oct;23(10):1346–1356. DOI:https://doi.org/10.1038/modpathol.2010.122.
- Brentnall TA, Lai LA, Coleman J, et al. Arousal of cancer-associated stroma: overexpression of palladin activates fibroblasts to promote tumor invasion. PloS One. 2012;7(1):e30219. DOI:https://doi.org/10.1371/journal.pone.0030219.
- Kojima Y, Acar A, Eaton EN, et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20009–20014. https://doi.org/10.1073/pnas.1013805107
- Zeisberg EM, Potenta S, Xie L, et al. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007 Nov 1;67(21):10123–10128. https://doi.org/10.1158/0008-5472.CAN-07-3127
- Kawase A, Ishii G, Nagai K, et al. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer. 2008 Sep 1;123(5):1053–1059. https://doi.org/10.1002/ijc.23611
- Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol. 2014;4:62.
- Lama VN, Phan SH. The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. Proc Am Thorac Soc. 2006 Jun;3(4):373–376.
- Jaster R. Molecular regulation of pancreatic stellate cell function. Mol Cancer. 2004 Oct 6;3(1):26. https://doi.org/10.1186/1476-4598-3-26
- Kidd S, Spaeth E, Watson K, et al. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PloS One. 2012;7(2):e30563. DOI:https://doi.org/10.1371/journal.pone.0030563.
- Ishii G, Sangai T, Oda T, et al. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun. 2003 Sep 12;309(1):232–240. https://doi.org/10.1016/S0006-291X(03)01544-4
- Ishii G, Ito TK, Aoyagi K, et al. Presence of human circulating progenitor cells for cancer stromal fibroblasts in the blood of lung cancer patients. Stem Cells. 2007 Jun;25(6):1469–1477. DOI:https://doi.org/10.1634/stemcells.2006-0449.
- Borriello L, Nakata R, Sheard MA, et al. Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells. Cancer Res. 2017 Sep 15;77(18):5142–5157. https://doi.org/10.1158/0008-5472.CAN-16-2586
- Vizoso M, Puig M, Carmona FJ, et al. Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts. Carcinogenesis. 2015 Dec;36(12):1453–1463.
- Trimboli AJ, Cantemir-Stone CZ, Li F, et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature. 2009 Oct 22;461(7267):1084–1091. https://doi.org/10.1038/nature08486
- Calon A, Espinet E, Palomo-Ponce S, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012 Nov 13;22(5):571–584. https://doi.org/10.1016/j.ccr.2012.08.013
- Zhang XH, Jin X, Malladi S, et al. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell. 2013 Aug 29;154(5):1060–1073. https://doi.org/10.1016/j.cell.2013.07.036
- Calon A, Lonardo E, Berenguer-Llergo A, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015 Apr;47(4):320–329. DOI:https://doi.org/10.1038/ng.3225.
- Malanchi I, Santamaria-Martinez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2011 Dec 7;481(7379):85–89. https://doi.org/10.1038/nature10694
- Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011 Mar 25;331(6024):1559–1564. https://doi.org/10.1126/science.1203543
- Chen WJ, Ho CC, Chang YL, et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun. 2014 Mar 25 5(1):3472. https://doi.org/10.1038/ncomms4472
- Wald O, Izhar U, Amir G, et al. Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: role in non-small cell lung cancer tumor proliferation. J Thorac Cardiovasc Surg. 2011 Jun;141(6):1503–1512. DOI:https://doi.org/10.1016/j.jtcvs.2010.11.056.
- Jung Y, Kim JK, Shiozawa Y, et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun. 2013;4(1):1795. DOI:https://doi.org/10.1038/ncomms2766.
- Lee KW, Yeo SY, Sung CO, et al. Twist1 is a key regulator of cancer-associated fibroblasts. Cancer Res. 2015 Jan 1;75(1):73–85. https://doi.org/10.1158/0008-5472.CAN-14-0350
- Wang Y, Lan W, Xu M, et al. Cancer-associated fibroblast-derived SDF-1 induces epithelial-mesenchymal transition of lung adenocarcinoma via CXCR4/beta-catenin/PPARdelta signalling. Cell Death Dis. 2021 Feb 26;12(2):214. https://doi.org/10.1038/s41419-021-03509-x
- Maxwell PJ, Neisen J, Messenger J, et al. Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget. 2014 Jul 15;5(13):4895–4908. https://doi.org/10.18632/oncotarget.2052
- Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005 May 6;121(3):335–348. https://doi.org/10.1016/j.cell.2005.02.034
- Yu Y, Xiao CH, Tan LD, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br J Cancer. 2014 Feb 4;110(3):724–732. https://doi.org/10.1038/bjc.2013.768
- Shintani Y, Abulaiti A, Kimura T, et al. Pulmonary fibroblasts induce epithelial mesenchymal transition and some characteristics of stem cells in non-small cell lung cancer. Ann Thorac Surg. 2013 Aug;96(2):425–433. DOI:https://doi.org/10.1016/j.athoracsur.2013.03.092.
- Sato R, Imamura K, Semba T, et al. TGF-beta signaling activated by cancer-associated fibroblasts determines the histological signature of lung adenocarcinoma. Cancer Res. 2021 Jul 21;81(18):4751–4765. https://doi.org/10.1158/0008-5472.CAN-20-3941
- Shintani Y, Fujiwara A, Kimura T, et al. IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling. J Thorac Oncol. 2016 Sep;11(9):1482–1492. DOI:https://doi.org/10.1016/j.jtho.2016.05.025.
- Ikemori R, Gabasa M, Duch P, et al. Epigenetic SMAD3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma. Cancer Res. 2020 Jan 15;80(2):276–290. https://doi.org/10.1158/0008-5472.CAN-19-0637
- Tyan SW, Kuo WH, Huang CK, et al. Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PloS One. 2011 Jan 13;6(1):e15313. https://doi.org/10.1371/journal.pone.0015313
- Jia CC, Wang TT, Liu W, et al. Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PloS One. 2013;8(5):e63243. DOI:https://doi.org/10.1371/journal.pone.0063243.
- Wu X, Chen X, Zhou Q, et al. Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer. Cancer Lett. 2013 Jul 10;335(1):128–135. https://doi.org/10.1016/j.canlet.2013.02.002
- Ding X, Ji J, Jiang J, et al. HGF-mediated crosstalk between cancer-associated fibroblasts and MET-unamplified gastric cancer cells activates coordinated tumorigenesis and metastasis. Cell Death Dis. 2018 Aug 29;9(9):867. https://doi.org/10.1038/s41419-018-0922-1
- Ying L, Zhu Z, Xu Z, et al. Cancer associated fibroblast-derived hepatocyte growth factor inhibits the paclitaxel-induced apoptosis of lung cancer A549 cells by up-regulating the PI3K/Akt and GRP78 signaling on a microfluidic platform. PloS One. 2015;10(6):e0129593. DOI:https://doi.org/10.1371/journal.pone.0129593.
- Suzuki E, Yamazaki S, Naito T, et al. Secretion of high amounts of hepatocyte growth factor is a characteristic feature of cancer-associated fibroblasts with EGFR-TKI resistance-promoting phenotype: a study of 18 cases of cancer-associated fibroblasts. Pathol Int. 2019 Aug;69(8):472–480. DOI:https://doi.org/10.1111/pin.12838.
- Wang W, Li Q, Yamada T, et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 2009 Nov 1;15(21):6630–6638. https://doi.org/10.1158/1078-0432.CCR-09-1001
- Otomo R, Otsubo C, Matsushima-Hibiya Y, et al. TSPAN12 is a critical factor for cancer-fibroblast cell contact-mediated cancer invasion. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18691–18696. https://doi.org/10.1073/pnas.1412062112
- Camp JT, Elloumi F, Roman-Perez E, et al. Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. Mol Cancer Res. 2011 Jan;9(1):3–13. DOI:https://doi.org/10.1158/1541-7786.MCR-10-0372.
- Arrigoni C, De Luca P, Gilardi M, et al. Direct but not indirect co-culture with osteogenically differentiated human bone marrow stromal cells increases RANKL/OPG ratio in human breast cancer cells generating bone metastases. Mol Cancer. 2014 Oct 21 13(1):238. https://doi.org/10.1186/1476-4598-13-238
- Luga V, Zhang L, Viloria-Petit AM, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012 Dec 21;151(7):1542–1556. https://doi.org/10.1016/j.cell.2012.11.024
- Miki Y, Yashiro M, Okuno T, et al. CD9-positive exosomes from cancer-associated fibroblasts stimulate the migration ability of scirrhous-type gastric cancer cells. Br J Cancer. 2018 Mar 20;118(6):867–877. https://doi.org/10.1038/bjc.2017.487
- Yang X, Li Y, Zou L, et al. Role of exosomes in crosstalk between cancer-associated fibroblasts and cancer cells. Front Oncol. 2019;9:356.
- Au Yeung CL, Co NN, Tsuruga T, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016 Mar 29 7(1):11150. https://doi.org/10.1038/ncomms11150
- Bhome R, Goh RW, Bullock MD, et al. Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression. Aging (Albany NY). 2017 Dec 28;9(12):2666–2694. https://doi.org/10.18632/aging.101355
- Donnarumma E, Fiore D, Nappa M, et al. Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget. 2017 Mar 21;8(12):19592–19608. https://doi.org/10.18632/oncotarget.14752
- Bica-Pop C, Cojocneanu-Petric R, Magdo L, et al. Overview upon miR-21 in lung cancer: focus on NSCLC. Cell Mol Life Sci. 2018 Oct;75(19):3539–3551. DOI:https://doi.org/10.1007/s00018-018-2877-x.
- Kunita A, Morita S, Irisa TU, et al. MicroRNA-21 in cancer-associated fibroblasts supports lung adenocarcinoma progression. Sci Rep. 2018 Jun 11;8(1):8838. https://doi.org/10.1038/s41598-018-27128-3
- Chen Y, Zeng C, Zhan Y, et al. Aberrant low expression of p85alpha in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b. Oncogene. 2017 Aug 17;36(33):4692–4705. https://doi.org/10.1038/onc.2017.100
- Li W, Zhang X, Wang J, et al. TGFbeta1 in fibroblasts-derived exosomes promotes epithelial-mesenchymal transition of ovarian cancer cells. Oncotarget. 2017 Nov 10;8(56):96035–96047. https://doi.org/10.18632/oncotarget.21635
- Hu YB, Yan C, Mu L, et al. Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance. Oncogene. 2019 Mar;38(11):1951–1965. DOI:https://doi.org/10.1038/s41388-018-0557-9.
- Zhao H, Yang L, Baddour J, et al. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. Elife. 2016 Feb 27;5:e10250. https://doi.org/10.7554/eLife.10250.
- Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212–20217. https://doi.org/10.1073/pnas.1320318110
- Cremasco V, Astarita JL, Grauel AL, et al. FAP delineates heterogeneous and functionally divergent stromal cells in immune-excluded breast tumors. Cancer Immunol Res. 2018 Dec;6(12):1472–1485. DOI:https://doi.org/10.1158/2326-6066.CIR-18-0098.
- Sakai T, Aokage K, Neri S, et al. Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma. Lung Cancer. 2018 Dec;126:64–71.
- Suzuki J, Aokage K, Neri S, et al. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer. 2021 Mar;153:1–10.
- Kinoshita T, Ishii G, Hiraoka N, et al. Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with a poor outcome in lung adenocarcinoma. Cancer Sci. 2013 Apr;104(4):409–415. DOI:https://doi.org/10.1111/cas.12099.
- Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018 Mar 12;33(3):463–479 e10. https://doi.org/10.1016/j.ccell.2018.01.011
- Lakins MA, Ghorani E, Munir H, et al. Cancer-associated fibroblasts induce antigen-specific deletion of CD8+T cells to protect tumour cells. Nat Commun. 2018 Mar 5;9(1):948. https://doi.org/10.1038/s41467-018-03347-0
- Cho H, Seo Y, Loke KM, et al. Cancer-stimulated cafs enhance monocyte differentiation and protumoral TAM activation via IL6 and GM-CSF secretion. Clin Cancer Res. 2018 Nov 1;24(21):5407–5421. https://doi.org/10.1158/1078-0432.CCR-18-0125
- Comito G, Giannoni E, Segura CP, et al. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene. 2014 May 8;33(19):2423–2431. https://doi.org/10.1038/onc.2013.191
- Augsten M, Sjoberg E, Frings O, et al. Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties. Cancer Res. 2014 Jun 1;74(11):2999–3010. https://doi.org/10.1158/0008-5472.CAN-13-2740
- De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017 Aug;17(8):457–474.
- Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014 Dec;15(12):786–801.
- Manegold C, Dingemans AC, Gray JE, et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol. 2017 Feb;12(2):194–207. DOI:https://doi.org/10.1016/j.jtho.2016.10.003.
- Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011 Aug 16;21(2):193–215. https://doi.org/10.1016/j.devcel.2011.07.001
- Boire A, Covic L, Agarwal A, et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005 Feb 11;120(3):303–313. https://doi.org/10.1016/j.cell.2004.12.018
- Gaggioli C, Hooper S, Hidalgo-Carcedo C, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol. 2007 Dec;9(12):1392–1400. DOI:https://doi.org/10.1038/ncb1658.
- Sanz-Moreno V, Gaggioli C, Yeo M, et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell. 2011 Aug 16;20(2):229–245. https://doi.org/10.1016/j.ccr.2011.06.018
- Scott RW, Hooper S, Crighton D, et al. LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J Cell Biol. 2010 Oct 4;191(1):169–185. https://doi.org/10.1083/jcb.201002041
- Neri S, Ishii G, Hashimoto H, et al. Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. Int J Cancer. 2015 Aug 15;137(4):784–796. https://doi.org/10.1002/ijc.29464
- Labernadie A, Kato T, Brugues A, et al. A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nat Cell Biol. 2017 Mar;19(3):224–237. DOI:https://doi.org/10.1038/ncb3478.
- Neri S, Miyashita T, Hashimoto H, et al. Fibroblast-led cancer cell invasion is activated by epithelial-mesenchymal transition through platelet-derived growth factor BB secretion of lung adenocarcinoma. Cancer Lett. 2017 Jun 1;395:20–30. https://doi.org/10.1016/j.canlet.2017.02.026.
- Ito S, Ishii G, Hoshino A, et al. Tumor promoting effect of podoplanin-positive fibroblasts is mediated by enhanced RhoA activity. Biochem Biophys Res Commun. 2012 May 25;422(1):194–199. https://doi.org/10.1016/j.bbrc.2012.04.158
- Green JL, La J, Yum KW, et al. Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6991–6996. https://doi.org/10.1073/pnas.1303671110
- Engle SJ, Hoying JB, Boivin GP, et al. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res. 1999 Jul 15;59(14):3379–3386.
- Flaberg E, Markasz L, Petranyi G, et al. High-throughput live-cell imaging reveals differential inhibition of tumor cell proliferation by human fibroblasts. Int J Cancer. 2011 Jun 15;128(12):2793–2802. https://doi.org/10.1002/ijc.25612
- Takahashi A, Ishii G, Neri S, et al. Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth. Oncotarget. 2015 Apr 20;6(11):9531–9541. https://doi.org/10.18632/oncotarget.3371
- Mizutani Y, Kobayashi H, Iida T, et al. Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res. 2019 Oct 15;79(20):5367–5381. https://doi.org/10.1158/0008-5472.CAN-19-0454
- Domen A, Quatannens D, Zanivan S, et al. Cancer-associated fibroblasts as a common orchestrator of therapy resistance in lung and pancreatic cancer. Cancers (Basel). 2021 Feb 27;13(5):987. https://doi.org/10.3390/cancers13050987
- Ishii G, Ochiai A, Neri S. Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):186–196. https://doi.org/10.1016/j.addr.2015.07.007
- Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Jul 26;487(7408):500–504. https://doi.org/10.1038/nature11183
- Yoshida T, Ishii G, Goto K, et al. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clin Cancer Res. 2015 Feb 1;21(3):642–651. https://doi.org/10.1158/1078-0432.CCR-14-0846
- Yamazaki S, Higuchi Y, Ishibashi M, et al. Collagen type I induces EGFR-TKI resistance in EGFR-mutated cancer cells by mTOR activation through Akt-independent pathway. Cancer Sci. 2018 Jun;109(6):2063–2073. DOI:https://doi.org/10.1111/cas.13624.
- Yamazaki S, Su Y, Maruyama A, et al. Uptake of collagen type I via macropinocytosis cause mTOR activation and anti-cancer drug resistance. Biochem Biophys Res Commun. 2020 May 21;526(1):191–198. https://doi.org/10.1016/j.bbrc.2020.03.067
- Hashimoto H, Suda Y, Miyashita T, et al. A novel method to generate single-cell-derived cancer-associated fibroblast clones. J Cancer Res Clin Oncol. 2017 Aug;143(8):1409–1419. DOI:https://doi.org/10.1007/s00432-017-2409-3.
- Ishibashi M, Neri S, Hashimoto H, et al. CD200-positive cancer associated fibroblasts augment the sensitivity of epidermal growth factor receptor mutation-positive lung adenocarcinomas to EGFR tyrosine kinase inhibitors. Sci Rep. 2017 Apr 21 7(1):46662. https://doi.org/10.1038/srep46662
- Antony J, Huang RY. AXL-driven EMT state as a targetable conduit in cancer. Cancer Res. 2017 Jul 15;77(14):3725–3732. https://doi.org/10.1158/0008-5472.CAN-17-0392
- Kanzaki R, Naito H, Kise K, et al. Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy. Sci Rep. 2017 Sep 6;7(1):10613. https://doi.org/10.1038/s41598-017-10873-2
- Su S, Chen J, Yao H, et al. CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell. 2018 Feb 8;172(4):841–856 e16. https://doi.org/10.1016/j.cell.2018.01.009
- Hu Y, Yan C, Mu L, et al. Fibroblast-derived exosomes contribute to chemoresistance through priming cancer stem cells in colorectal cancer. PloS One. 2015;10(5):e0125625. DOI:https://doi.org/10.1371/journal.pone.0125625.
- Hu JL, Wang W, Lan XL, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019 May 7;18(1):91. https://doi.org/10.1186/s12943-019-1019-x
- Valkenburg KC, de Groot Ae, Pienta KJ, et al. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15(6):366–381.
- Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009 Jun 12;324(5933):1457–1461. https://doi.org/10.1126/science.1171362
- Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012 Mar 20;21(3):418–429. https://doi.org/10.1016/j.ccr.2012.01.007
- Dangi-Garimella S, Krantz SB, Barron MR, et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 2011 Feb 1;71(3):1019–1028. https://doi.org/10.1158/0008-5472.CAN-10-1855
- Dangi-Garimella S, Sahai V, Ebine K, et al. Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression. PloS One. 2013;8(5):e64566. DOI:https://doi.org/10.1371/journal.pone.0064566.
- Ishii G, Ishii T. Review of cancer-associated fibroblasts and their microenvironment in post-chemotherapy recurrence. Hum Cell. 2020 Oct;33(4):938–945.
- Sun Y, Campisi J, Higano C, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012 Sep;18(9):1359–1368. DOI:https://doi.org/10.1038/nm.2890.
- Ishii T, Suzuki A, Kuwata T, et al. Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapy. Gastric Cancer. 2021 Jul;24(4):810–822. DOI:https://doi.org/10.1007/s10120-021-01174-9.
- Hisamitsu S, Miyashita T, Hashimoto H, et al. Interaction between cancer cells and cancer-associated fibroblasts after cisplatin treatment promotes cancer cell regrowth. Hum Cell. 2019 Oct;32(4):453–464. DOI:https://doi.org/10.1007/s13577-019-00275-z.
- Mitsuhashi A, Goto H, Saijo A, et al. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun. 2015 Dec 4 6(1):8792. https://doi.org/10.1038/ncomms9792
- Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2009 Jan 6;15(1):21–34. https://doi.org/10.1016/j.ccr.2008.12.004
- Nazareth MR, Broderick L, Simpson-Abelson MR, et al. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol. 2007;178(9):5552–5562. DOI:https://doi.org/10.4049/jimmunol.178.9.5552.
- Ford K, Hanley CJ, Mellone M, et al. NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors. Cancer Res. 2020 May 1;80(9):1846–1860. https://doi.org/10.1158/0008-5472.CAN-19-3158
- Hanley CJ, Thomas GJ. T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting. Br J Cancer. 2020 Oct;123(9):1353–1355.
- Kieffer Y, Hocine HR, Gentric G, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020 Sep;10(9):1330–1351. DOI:https://doi.org/10.1158/2159-8290.CD-19-1384.
- Hofheinz RD, Al-batran SE, Hartmann F, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 2003 Feb;26(1):44–48. DOI:https://doi.org/10.1159/000069863.
- Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639–1647.
- Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006 Apr 15;66(8):4426–4433. https://doi.org/10.1158/0008-5472.CAN-05-4489
- Ostermann E, Garin-Chesa P, Heider KH, et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res. 2008 Jul 15;14(14):4584–4592. https://doi.org/10.1158/1078-0432.CCR-07-5211
- LeBeau AM, Brennen WN, Aggarwal S, et al. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol Cancer Ther. 2009 May;8(5):1378–1386. DOI:https://doi.org/10.1158/1535-7163.MCT-08-1170.
- Demircioglu F, Wang J, Candido J, et al. Cancer associated fibroblast FAK regulates malignant cell metabolism. Nat Commun. 2020 Mar 10;11(1):1290. https://doi.org/10.1038/s41467-020-15104-3
- Gerber DE, Camidge DR, Morgensztern D, et al. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer. 2020 Jan;139:60–67.
- Schuler M, Cho BC, Sayehli CM, et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019 Oct;20(10):1454–1466. DOI:https://doi.org/10.1016/S1470-2045(19)30412-7.
- Nogova L, Sequist LV, Perez Garcia JM, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase i, dose-escalation and dose-expansion study. J Clin Oncol. 2017 Jan 10;35(2):157–165. https://doi.org/10.1200/JCO.2016.67.2048
- Altorki NK, Markowitz GJ, Gao D, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019 Jan;19(1):9–31. DOI:https://doi.org/10.1038/s41568-018-0081-9.
- Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014 Feb;15(2):143–155. DOI:https://doi.org/10.1016/S1470-2045(13)70586-2.
- Scagliotti GV, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol. 2012 Aug 10;30(23):2829–2836. https://doi.org/10.1200/JCO.2011.41.4987
- Paz-Ares L, Hirsh V, Zhang L, et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer (mission) trial: a phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J Thorac Oncol. 2015 Dec;10(12):1745–1753. DOI:https://doi.org/10.1097/JTO.0000000000000693.
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119–1131. https://doi.org/10.1056/NEJMoa1707914
- Wong CC, Baum J, Silvestro A, et al. Inhibition of IL1beta by Canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial. Cancer Res. 2020 Dec 15;80(24):5597–5605. https://doi.org/10.1158/0008-5472.CAN-19-3176
- Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Aug 23;384(9944):665–673. https://doi.org/10.1016/S0140-6736(14)60845-X
- Chiappori AA, Eckhardt SG, Bukowski R, et al. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2091–2099. https://doi.org/10.1158/1078-0432.CCR-06-1586